CORRESP Filing
Sunshine Biopharma Inc.
Date: Aug. 11, 2025 · CIK: 0001402328 · Accession: 0001683168-25-005883
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289230
Letter
Sunshine Biopharma Inc.
333 Las Olas Way
CU4 Suite 433
Fort Lauderdale, FL 33301
August 11, 2025
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Sunshine Biopharma Inc.
Registration Statement on Form S-1
Filed August 5, 2025
File No. 333-289230
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sunshine Biopharma Inc. hereby respectfully requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, August 12, 2025, or as soon as practicable thereafter.
Very truly yours,
Sunshine Biopharma Inc.
Show Raw Text
CORRESP 1 filename1.htm Sunshine Biopharma Inc. 333 Las Olas Way CU4 Suite 433 Fort Lauderdale, FL 33301 August 11, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Sunshine Biopharma Inc. Registration Statement on Form S-1 Filed August 5, 2025 File No. 333-289230 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sunshine Biopharma Inc. hereby respectfully requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, August 12, 2025, or as soon as practicable thereafter. Very truly yours, Sunshine Biopharma Inc. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty Chief Executive Officer